| Type | Public |
| HQ | Lexington, US |
| Founded | 1994 |
| Size (employees) | 255 (est) |
| Website | agenusbio.com |
Agenus was founded in 1994 and is headquartered in Lexington, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Agenus
Garo Armen
PhD, Chairman and CEO
Jennifer Buell
PhD, Chief Operating Officer
Ozer Baysal
Chief Commercial Officer and Head of Human Resources
Alex Duncan
PhD, Chief Technology Officer and Head of Research
Christian Cortis
PhD, Chief Strategy Officer & Head of Finance
Report incorrect company information
Agenus Office Locations
Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Road
Berkeley, US
793 Heinz Ave
New York, US
149 Fifth Ave. Suite 500
Cambridge, GB
315 Science Park Milton Road
Report incorrect company information
Agenus Financials and Metrics
Agenus Revenue
Agenus's revenue was reported to be $42.88 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 12.8m |
Net income (Q3, 2018) | (33.7m) |
EBIT (Q3, 2018) | (26.1m) |
Market capitalization (14-Dec-2018) | 290.4m |
Closing stock price (14-Dec-2018) | 2.4 |
Cash (30-Sep-2018) | 46.2m |
EV | 257.4m |
Agenus's current market capitalization is $290.4 m.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 736.0k | 720.9k | 3.1m | 1.6m | 4.0m | 6.4m | 6.8m | 6.0m | 6.6m | 4.4m | 27.0m | 4.2m | 3.4m | 1.6m | 15.9m | 12.8m |
General and administrative expense | 3.6m | 5.2m | 5.8m | 4.9m | 5.5m | 8.0m | 6.4m | 9.2m | 7.1m | 8.1m | 7.8m | 8.1m | 8.1m | 8.9m | 9.5m | 9.2m |
R&D expense | 3.9m | 4.5m | 5.2m | 5.3m | 9.2m | 24.8m | 18.5m | 5.8m | 6.6m | 4.4m | 27.0m | 4.2m | 3.4m | 29.4m | 29.3m | 29.9m |
Operating expense total | 7.5m | 9.6m | 11.1m | 10.2m | 14.7m | 32.8m | 24.9m | 15.0m | 13.7m | 12.6m | 34.7m | 12.3m | 11.4m | 38.4m | 77.1m | 39.1m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 30.2m | 73.5m | 48.3m | 38.4m | 79.3m | 124.7m | 184.1m | 78.3m | 73.4m | 75.4m | 113.9m | 81.8m | 65.1m | 52.3m | 43.2m | 46.2m |
Accounts Receivable | 1.1k | 2.5m | 4.1m | 7.3m | 10.2m | 9.4m | 10.3m | 6.8m | 3.9m | 2.2m | 1.1m | 10.9m | 6.1m | |||
Inventories | 3.3k | 95.7k | 95.7k | 88.2k | 88.2k | 88.2k | 88.2k | 88.2k | 88.2k | 87.5k | 87.0k | 80.2k | 62.2k | 55.5k | 55.5k | |
Current Assets | 30.9m | 75.3m | 67.0m | 55.2m | 85.2m | 146.3m | 208.9m | 161.6m | 136.1m | 109.5m | 138.0m | 110.7m | 84.3m | 65.2m | 67.7m | 67.6m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (24.3m) | (357.5k) | (8.4m) | (16.5m) | (18.7m) | (59.2m) | (72.3m) | (31.8m) | (60.1m) | (100.9m) | (17.1m) | (48.8m) | (85.7m) | (54.3m) | (79.5m) | (113.2m) |
Depreciation and Amortization | 448.2k | 266.5k | 589.4k | 1.0m | 445.5k | 885.5k | 1.4m | 1.2m | 2.5m | 3.7m | 1.5m | 3.1m | 4.6m | 1.6m | 3.1m | 4.7m |
Inventories | 12.7k | (95.7k) | (95.7k) | 7.5k | 7.5k | 7.5k | 88.2k | 88.2k | 88.2k | 87.5k | 8.0k | 17.3k | 24.0k | 24.0k | ||
Accounts Payable | (269.4k) | 184.0k | (562.1k) | 35.2k | 2.3m | 797.8k | 1.3m | (2.3m) | 474.5k | (1.3m) | (1.1m) | (1.2m) | 1.0m | (2.8m) | 1.7m | 2.9m |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -9.9 x |
EV/CFO | -2.7 x |
Debt/Equity | -0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -1 x |
Report incorrect company information
Agenus Online and Social Media Presence
1.09k Twitter followers
Agenus has 1.09k Twitter Followers. The number of followers has decreased 2% month over month and increased 7.6% quarter over quarter
Report incorrect company information
Agenus News and Updates
November 13, 2018
Agenus to Present at the 2018 Jefferies London Healthcare Conference
LEXINGTON, Mass., Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will...
November 06, 2018
Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018
LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new data on several of its programs – including AutoSynVax™ (ASV™), discovery...
November 06, 2018
Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the third quarter of...
October 31, 2018
Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass., Oct. 31, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its third quarter 2018 financial results before the market opens on Tuesday,...
October 23, 2018
Global Checkpoint Inhibitors Markets 2018-2023 with Profiles of Agenus, BeiGene, BIOCAD, Forty Seven, Seattle Genetics, Shanghai Cell Therapy, Tesaro and Xencor
DUBLIN, Oct. 23, 2018 /PRNewswire/ -- The "Checkpoint Inhibitors: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates ...
October 20, 2018
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
LEXINGTON, Mass., Oct. 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies2, presented updated clinical data on its lead CTLA-4 and PD-1 programs today at the 2018...
Report incorrect company information
Agenus Blogs
October 20, 2018
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses
October 09, 2018
Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018
- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer
August 09, 2018
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- Cash milestones earned from Merck & Incyte
Agenus Company Life and Culture
Report incorrect company information
 Agenus Frequently Asked Questions
When was Agenus founded?
Agenus was founded in 1994.
Who are Agenus key executives?
Agenus's key executives are Garo Armen, Jennifer Buell and Ozer Baysal.
How many employees does Agenus have?
Agenus has 255 employees.
What is Agenus revenue?
Latest Agenus annual revenue is $42.9 m.
What is Agenus revenue per employee?
Latest Agenus revenue per employee is $168.1 k.
Who are Agenus competitors?
Competitors of Agenus include Regeneron Pharmaceuticals, ImmunoCellular Therapeutics and Medivir.
Where is Agenus headquarters?
Agenus headquarters is located at 3 Forbes Road , Lexington.
Where are Agenus offices?
Agenus has offices in Lexington, Berkeley, New York and Cambridge.
How many offices does Agenus have?
Agenus has 4 offices.